| 摘要 |
A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) in a biological sample, such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related to nephropathy, retinopathy or cardiovascular complications. The preferred biomarkers to measure include N µ -(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N µ -carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes complications and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products. |
